Skip to main content
SpringerLink
Log in

Is Cystatin C Good Enough as a Biomarker for Vancomycin Dosing: A Pharmacokinetic Perspective

  • Commentary
  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

The Original Article was published on 20 September 2019

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function–measured and estimated glomerular filtration rate. N Engl J Med. 2006;354(23):2473–83.

    Article  CAS  Google Scholar 

  2. Rodieux F, Wilbaux M, van den Anker JN, Pfister M. Effect of kidney function on drug kinetics and dosing in neonates, infants, and children. Clin Pharmacokinet. 2015;54:1183–204.

    Article  CAS  Google Scholar 

  3. Panteghini M. Enzymatic assays for creatinine: time for action. Clin Chem Lab Med. 2008;46(4):567–72.

    CAS  PubMed  Google Scholar 

  4. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20–9.

    Article  CAS  Google Scholar 

  5. Grubb A, Nyman U, Björk J, Lindström V, Rippe B, Sterner G, et al. Simple cystatin C-based prediction equations for glomerular filtration rate compared with the modification of diet in renal disease prediction equation for adults and the Schwartz and the Counahan-Barratt prediction equations for children. Clin Chem. 2005;51(8):1420–31.

    Article  CAS  Google Scholar 

  6. Ye X, Liu X, Song D, Zhang X, Zhu B, Wei L, et al. Estimating glomerular filtration rate by serum creatinine or/and cystatin C equations: an analysis of multi-centre Chinese subjects. Nephrology. 2016;21(5):372–8.

    Article  CAS  Google Scholar 

  7. Mysliwiec P, Jasiewicz P, Hady HR, Choromanska B, Mroczko B, Mysliwiec H, et al. Creatinine or cystatin C – which is a better index of renal function in morbid obesity? Adv Med Sci. 2013;58(2):376–81.

    Article  CAS  Google Scholar 

  8. Zhang R, Chen M, Liu TT, Lu JJ, Lv CL. Comparison of the predictive performance between cystatin C and serum creatinine by vancomycin via a population pharmacokinetic models: a prospective study in a Chinese population. Eur J Drug Metab Pharmacokinet. 2019. https://doi.org/10.1007/s13318-019-00578-4.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Jing L, Liu TT, Guo Q, Chen M, Lu JJ, Lv CL. Development and comparison of population pharmacokinetic models of vancomycin in neurosurgical patients based on two different renal function markers. J Clin Pharm Ther. 2019. https://doi.org/10.1111/jcpt.13029.

    Article  PubMed  Google Scholar 

  10. Liu TT, Pang HM, Jing L, Wei WX, Qin XL, Guo Q, et al. A population pharmacokinetic model of vancomycin for dose individualization based on serum cystatin C as a marker of renal function. J Pharm Pharmacol. 2019;71(6):945–55.

    Article  CAS  Google Scholar 

  11. Frazee E, Rule AD, Lieske JC, Kashani KB, Barreto JN, Virk A, et al. Cystatin C-guided vancomycin dosing in critically Ill patients: a quality improvement project. Am J Kidney Dis. 2017;69(5):658–66.

    Article  CAS  Google Scholar 

  12. Shin JE, Lee SM, Eun HS, Park MS, Park KI, Namgung R. Usefulness of serum cystatin C to determine the dose of vancomycin in neonate. Korean J Pediatr. 2015;58(11):421–6.

    Article  CAS  Google Scholar 

  13. DeCarolis DD, Thorson JG, Marraffa RA, Clairmont MA, Kuskowski MA. Comparison of equations with estimate renal function to predict serum vancomycin concentration in patients with spinal cord injury–does the use of cystatin C improve accuracy? Ther Drug Monit. 2014;36(5):632–9.

    Article  CAS  Google Scholar 

  14. Frazee EN, Rule AD, Herrmann SM, Kashani KB, Leung N, Virk A, et al. Serum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized patients: a cohort study. Crit Care. 2014;18(3):R110.

    Article  Google Scholar 

  15. Chen YC, Feng JF, Li B, Zhang L, Yang YW. Estimation of safe and effective dose of vancomycin in MRSA-infected patients using serum cystatin C concentrations. Int J Clin Pharmacol Ther. 2013;51(3):161–9.

    Article  CAS  Google Scholar 

  16. Chung JY, Jin SJ, Yoon JH, Song YG. Serum cystatin C is a major predictor of vancomycin clearance in a population pharmacokinetic analysis of patients with normal serum creatinine concentrations. J Korean Med Sci. 2013;28(1):48–54.

    Article  CAS  Google Scholar 

  17. Kees MG, Hilpert JW, Gnewuch C, Kees F, Voegeler S. Clearance of vancomycin during continuous infusion in Intensive Care Unit patients: correlation with measured and estimated creatinine clearance and serum cystatin C. Int J Antimicrob Agents. 2010;36(6):545–8.

    Article  CAS  Google Scholar 

  18. Suzuki A, Imanishi Y, Nakano S, Niwa T, Ohmori T, Shirai K, et al. Usefulness of serum cystatin C to determine the dose of vancomycin in critically ill patients. J Pharm Pharmacol. 2010;62(7):901–7.

    Article  CAS  Google Scholar 

  19. Tanaka A, Aiba T, Otsuka T, Suemaru K, Nishimiya T, Inoue T, et al. Population pharmacokinetic analysis of vancomycin using serum cystatin C as a marker of renal function. Antimicrob Agents Chemother. 2010;54(2):778–82.

    Article  CAS  Google Scholar 

  20. Okamoto G, Sakamoto T, Kimura M, Ukishima Y, Sonoda A, Mori N, et al. Serum cystatin C as a better marker of vancomycin clearance than serum creatinine in elderly patients. Clin Biochem. 2007;40(7):485–90.

    Article  CAS  Google Scholar 

  21. Tanaka A, Suemaru K, Otsuka T, Ido K, Nishimiya T, Sakai I, et al. Estimation of the initial dose setting of vancomycin therapy with use of cystatin C as a new marker of renal function. Ther Drug Monit. 2007;29(2):261–4.

    Article  CAS  Google Scholar 

  22. Hermida J, Tutor JC. Serum cystatin C for the prediction of glomerular filtration rate with regard to the dose adjustment of amikacin, gentamicin, tobramycin, and vancomycin. Ther Drug Monit. 2006;28(3):326–31.

    Article  CAS  Google Scholar 

  23. Hoek FJ, Kemperman FA, Krediet RT. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant. 2003;18(10):2024–31.

    Article  CAS  Google Scholar 

  24. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.

    Article  CAS  Google Scholar 

  25. Li GF, Zheng QS. Modeling drug disposition and drug-drug interactions through hypothesis-driven physiologically based pharmacokinetics: a reversal translation perspective. Eur J Drug Metab Pharmacokinet. 2018;43(3):369–71.

    Article  CAS  Google Scholar 

  26. Li GF, Zheng QS, Yu Y, Zhong W, Zhou HH, Qiu F, et al. Impact of ethnicity-specific hepatic microsomal scaling factor, liver weight, and CYP1A2 content on physiologically-based prediction of CYP1A2-mediated pharmacokinetics in young and elderly Chinese adults. Clin Pharmacokinet. 2019;58(7):927–41.

    Article  Google Scholar 

  27. Li GF, Yu G, Li Y, Zheng Y, Zheng QS, Derendorf H. Quantitative estimation of plasma free drug fraction in patients with varying degrees of hepatic impairment: a methodological evaluation. J Pharm Sci. 2018;107(7):1948–56.

    Article  CAS  Google Scholar 

  28. Yu G, Zhou HH, Zheng QS, Li GF. Interethnic scaling of fraction unbound of a drug in plasma and volume of distribution: an analysis of extrapolation from Caucasians to Chinese. Eur J Clin Pharmacol. 2019;75(4):543–51.

    Article  CAS  Google Scholar 

  29. Fernandez-Prado R, Castillo-Rodriguez E, Velez-Arribas FJ, Gracia-Iguacel C, Ortiz A. Creatinine clearance is not equal to glomerular filtration rate and Cockcroft-Gault equation is not equal to CKD-EPI collaboration equation. Am J Med. 2016;129(12):1259–63.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institution of Drug Clinical Trial, Subei People’s Hospital, #98 West Nantong Rd, Yangzhou, Jiangsu, 225001, China

    Guo Yu & Guo-Fu Li

  2. College of Pharmacy, Dalian Medical University, Dalian, Liaoning, China

    Guo Yu

Authors
  1. Guo Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guo-Fu Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Guo-Fu Li.

Ethics declarations

Funding

No funding was used for this work.

Conflict of interest

The authors have no conflicts of interest to declare.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yu, G., Li, GF. Is Cystatin C Good Enough as a Biomarker for Vancomycin Dosing: A Pharmacokinetic Perspective. Eur J Drug Metab Pharmacokinet 45, 151–156 (2020). https://doi.org/10.1007/s13318-019-00587-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13318-019-00587-3

Search

Navigation